© 2025 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY
WEDW-FM · WNPR · WPKT · WRLI-FM
Public Files Contact · ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

The World Could Be On The Verge Of Losing A Powerful Malaria Drug

A mother holds her ailing son at a special clinic for malaria in Myanmar.
Paula Bronstein
/
Getty Images
A mother holds her ailing son at a special clinic for malaria in Myanmar.

A new study finds a disturbing trend in the battle against malaria. There are highly effective drugs called artemisinins — and now resistant malaria is turning up in parts of Myanmar, the reclusive country also known as Burma, where it hadn't been seen before.

The study was conducted by Dr. Charles Woodrow and his colleagues at the Mahidol-Oxford Tropical Medicine Research Unit in Bangkok.

"Particularly toward the north, resistance is certainly present as we highlight and now lies quite close to the northwest border with India," Woodrow says.

There's concern that if the resistance takes root in India, it could quickly jump to other parts of the world.

Indeed, the drug-resistant strain is already a problem on the other side of Myanmar along the frontier with Thailand. And it's widespread in Cambodia.

"In parts of Cambodia," says Woodrow, "we are really down to the last possibilities in terms of how we treat malaria. We are considering combining three drugs, extending courses from three days up to five days. So I think midterm, this is a major problem."

The great concern is that Southeast Asia has historically been a graveyard for malaria drugs. In the 1960s, malaria parasites in Thailand learned how to fend off chloroquine, a first-line malaria drug. That resistance eventually spread around the globe. In sub-Saharan Africa, the loss of chloroquine cost hundreds of thousands of lives.

In the 1990s, artemisinin-based drugs from China became the new global standard for treating falciparum malaria, but studies like this one in Myanmar show that artemisinin resistance is growing. And this is a huge problem, because malaria, according to the World Health Organization, sickens almost 200 million people a year and kills roughly 600,000.

Woodrow says the resistance is developing slowly. In combination with other drugs, artemisinins are still effective. But he's not entirely optimistic: "If the parasites were to evolve in a way that made them entirely resistant to artemisinins, this would be disastrous over a short time scale. Because you'd be left with the remnants of all the other drugs we'd tried to use in the past."

He calls this the "nightmare scenario." The world is not there yet, but in what Woodrow calls the midterm — say, the next two to five years — he predicts that artemisinin-resistant malaria is going to be causing a lot of problems in Myanmar and elsewhere.

Copyright 2023 NPR. To see more, visit https://www.npr.org.

Jason Beaubien is NPR's Global Health and Development Correspondent on the Science Desk.

Fund the Facts

You just read trusted, local journalism that’s free for everyone, thanks to donors like you.

If that matters to you, now is the time to give. Join the 50,000+ members powering honest reporting and a more connected — and civil! — Connecticut.

SOMOS CONNECTICUT is an initiative from Connecticut Public, the state’s local NPR and PBS station, to elevate Latino stories and expand programming that uplifts and informs our Latino communities. Visit CTPublic.org/latino for more stories and resources. For updates, sign up for the SOMOS CONNECTICUT newsletter at ctpublic.org/newsletters.

SOMOS CONNECTICUT es una iniciativa de Connecticut Public, la emisora local de NPR y PBS del estado, que busca elevar nuestras historias latinas y expandir programación que alza y informa nuestras comunidades latinas locales. Visita CTPublic.org/latino para más reportajes y recursos. Para noticias, suscríbase a nuestro boletín informativo en ctpublic.org/newsletters.

Fund the Facts

You just read trusted, local journalism that’s free for everyone, thanks to donors like you.

If that matters to you, now is the time to give. Join the 50,000+ members powering honest reporting and a more connected — and civil! — Connecticut.

Related Content